Trial Profile
A 3-way cross-over, randomized, placebo-controlled, double-blind, multicenter study to assess the pharmacologic effects of a 7-day exposure to darifenacin 15 mg o.d. and tolterodine ER [extended release] 4 mg o.d on cardiovascular parameters in healthy subjects 50 years of age and older.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2007
Price :
$35
*
At a glance
- Drugs Darifenacin (Primary) ; Tolterodine (Primary)
- Indications Overactive bladder
- Focus Pharmacodynamics
- Sponsors Novartis
- 26 Oct 2007 Status changed from recruiting to completed.
- 10 Jan 2007 New trial record.